Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
Summary Baseline Demographic and Clinical Characteristics of REVITAHIP Participantsa VariablesActive (n = 111)Placebo (n = 107) P valueSex: n (%): Female84 (75.7)84 (78.5)0.633: Male27 (24.3)23 (21.5)Country of Birth: n (%): Australia92 (82.9)86 (80.4)0.727: Other19 (17.1)21 (19.6)Age Mean (years)b 83.7+/−7.584.1+/−7.00.726 Grouped: n (%): 65-74 yr15 (13.5)10 (9.3)0.772 to 75-84 yr43 (38.7)42 (39.3): 85-94 yr47 (42.3)50 (46.7): 95+ yr6 (5.4)5 (4.7)Body mass index (kg/m2)b 24.2+/−3.425.1+/−3.80.099Number of days from admission to loading doseb 4.8+/−2.15.4+/−2.30.049Pre-injury mobility: n (%)d: Fully independent80 (72.1)72 (67.9)0.156: Minimum help15 (13.5)15 (14.2): Moderately help8 (7.2)7 (6.6): Substantial help1 (0.9)8 (7.5): Unable to perform task7(6.3)4(3.8)Pre-injury Modified Barthel index87.5+/−19.986.9+/−22.20.852Pre-injury Functional Comorbidity Index b 3.37+/−2.12.9+/−1.70.063Hip Fracture Subtype: n (%)d: Undisplaced subcapital6 (5.7)3 (2.8)0.442: Displaced subcapital:50 (47.2)48 (45.3): Pertrochanteric simple (2-part)5 (4.7)5 (4.7): Pertrochanteric complex (3-part)27 (25.5)34 (21.1): Intertrochanteric/basicervical5 (4.7)9 (8.5): Subtrochanteric13 (12.3)7 (6.6)Time from fracture to surgery (in hours)b 43.8+/−38.938.9+/−25.90.272Hip Fracture Surgeryd 0.655: Cannulated screws4 (3.7)1 (0.9): Uncemented hemiarthroplasty15 (14.0)14 (13.2): Cemented hemiarthroplasty8 (7.5)9 (8.5): Total hip replacement19 (17.8)20 (18.9): Dynamic hip screw with short plate14 (13.1)8 (7.5): Dynamic hip screw with long plate19 (17.8)20 (18.9): Gamma nail28 (26.2)34 (32.1)MMSE score (mean, standard deviation)b 26.32+/−4.325.7+/−4.40.282Total number of medications usedb 5.1+/−2.64.9+/−2.60.20125-hydroxyvitamin D level (nmol/L)c Mean55.6+/−26.449.6+/−19.70.112 Grouped values: n (%)e: <3013 (16.5)11 (14.3)0.621 to 30-4922 (27.8)27 (35.1): > = 5044 (55.7)39 (50.6)Grip strength (kgs)b 16.4+/−7.315.7+/−6.20.478 aPlus-minus values are means +/− SD bContinuous variables were compared with the use of a two-sample t-test.
Source: Baseline characteristics and follow-up (Table 2). View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial
Source: Article title.
In this randomized, double-blind, placebo-controlled trial, 218 adults, aged 65-years or older, requiring hip fracture surgery were assigned to receive a single loading-dose of cholecalciferol (250,000 IU vitamin-D3, the REVITAHIP: Replenishment of Vitamin D in Hip Fracture strategy) or placebo, both receiving daily vitamin-D(800 IU) and calcium (500 mg) for 26-weeks.
Source: Abstract.
Patients were randomly assigned to receive either an oral loading dose of cholecalciferol (at a dose of 250,000 IU vitamin D3) or placebo, both receiving daily supplementation with oral vitamin D (800 IU) and calcium (500 mg).
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial
Randomised controlled trial · BMC Musculoskeletal Disorders · 2016
Original publication title
An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial
© The Author(s). 2016
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Improving vitamin D (25-OHD) status may be an important modifiable factor that could reduce disability severity, fall-rates and mortality associated after hip fracture surgery. Providing a loading-dose post-surgery may overcome limitations in adherence to daily supplementation.
Source: BackgroundAbstract: What methods does the paper describe?
In this randomized, double-blind, placebo-controlled trial, 218 adults, aged 65-years or older, requiring hip fracture surgery were assigned to receive a single loading-dose of cholecalciferol (250,000 IU vitamin-D3, the REVITAHIP: Replenishment of Vitamin D in Hip Fracture strategy) or placebo, both receiving daily vitamin-D(800 IU) and calcium (500 mg) for 26-weeks. Outcome measures were 2.4 m gait-velocity, falls, fractures, death (Week-4), 25-OHD levels, quality-of-life measure (EuroQoL) and mortality at weeks-2, 4 and 26.
Source: MethodAbstract: Results
Mean age of 218 participants was 83.9(7.2) years and 77.1 % were women. Baseline mean 25-OHD was 52.7(23.5)nmol/L, with higher levels at Week-2 (73 vs 66 nmol/L; p = .019) and Week-4 (83 vs 75 nmol/L; p = .030) in the Active-group, but not at Week-26. At week-4, there were no differences in 2.4 m gait-velocity (0.42 m/s vs 0.39 m/s, p = .490), fractures (2.7 % vs 2.8 %, p = .964) but Active participants reported less falls (6.3 % vs 21.1 %, χ2 = 4.327; p = 0.024), with no significant reduction in deaths at week-4 (1 vs 3, p = 0.295), higher percentage reporting ‘no pain or discomfort’ (96.4 % vs 88.8 %, p = 0.037), and trended for higher EuroQoL-scores (p = 0.092) at week-26.
One case of hypercalcemia at week-2 normalised by week-4.
Source: ResultsAbstract: Conclusion
Among older people after hip fracture surgery, the REVITAHIP strategy is a safe and low cost method of improving vitamin-D levels, reducing falls and pain levels.
Source: ConclusionAuthors’ abstract
Background
Improving vitamin D (25-OHD) status may be an important modifiable factor that could reduce disability severity, fall-rates and mortality associated after hip fracture surgery. Providing a loading-dose post-surgery may overcome limitations in adherence to daily supplementation.
Method
In this randomized, double-blind, placebo-controlled trial, 218 adults, aged 65-years or older, requiring hip fracture surgery were assigned to receive a single loading-dose of cholecalciferol (250,000 IU vitamin-D3, the REVITAHIP: Replenishment of Vitamin D in Hip Fracture strategy) or placebo, both receiving daily vitamin-D(800 IU) and calcium (500 mg) for 26-weeks. Outcome measures were 2.4 m gait-velocity, falls, fractures, death (Week-4), 25-OHD levels, quality-of-life measure (EuroQoL) and mortality at weeks-2, 4 and 26.
Results
Mean age of 218 participants was 83.9(7.2) years and 77.1 % were women. Baseline mean 25-OHD was 52.7(23.5)nmol/L, with higher levels at Week-2 (73 vs 66 nmol/L; p = .019) and Week-4 (83 vs 75 nmol/L; p = .030) in the Active-group, but not at Week-26. At week-4, there were no differences in 2.4 m gait-velocity (0.42 m/s vs 0.39 m/s, p = .490), fractures (2.7 % vs 2.8 %, p = .964) but Active participants reported less falls (6.3 % vs 21.1 %, χ2 = 4.327; p = 0.024), with no significant reduction in deaths at week-4 (1 vs 3, p = 0.295), higher percentage reporting ‘no pain or discomfort’ (96.4 % vs 88.8 %, p = 0.037), and trended for higher EuroQoL-scores (p = 0.092) at week-26.
One case of hypercalcemia at week-2 normalised by week-4.
Conclusion
Among older people after hip fracture surgery, the REVITAHIP strategy is a safe and low cost method of improving vitamin-D levels, reducing falls and pain levels.
Trial registration
The protocol for this study is registered with the Australian New Zealand Clinical Trials Registry ANZCTRN ACTRN12610000392066 (Date of registration: 14/05/2010).
Publication and source details
Original title: An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial
Jenson CS Mak; Rebecca S. Mason; Linda Klein; Ian D. Cameron
BMC Musculoskeletal Disorders · 2016
© The Author(s). 2016https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/501100001232Royal Australasian College of PhysiciansRACP AFRM Research Establishment FellowshipRACP Arnott Research Entry ScholarshipMak Jenson CSRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T17:18:19.142239+00:00
DOI: 10.1186/s12891-016-1174-9 · PMC4982117